Clinical trial · no report yet · Phase 1
SERENA-1
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
- NCT03616587 ↗
- Active not recruiting
- AstraZeneca
- 16 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 10 | |
| Podcasts | 3 | |
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women With ER-positive, HER2-negative Advanced Breast Cancer (SERENA-1)
- Phase
- Phase 1
- Status
- Active not recruiting
- Conditions
- ER+ HER2- Advanced Breast Cancer
- Interventions
- AZD9833; AZD9833; AZD9833 with palbociclib; AZD9833 with palbociclib; AZD9833 with everolimus; AZD9833 with everolimus; AZD9833 with abemaciclib; AZD9833 with abemaciclib; AZD9833 with capivasertib; AZD9833 with capivasertib; AZD9833 with ribociclib; AZD9833 with ribociclib; AZD9833 with anastrozole; AZD9833 with anastrozole
- Arms
- AZD9833 monotherapy dose escalation · Experimental
- AZD9833 monotherapy dose expansion · Experimental
- AZD9833 with palbociclib dose escalation · Experimental
- AZD9833 with palbociclib dose expansion · Experimental
- AZD9833 with everolimus dose expansion · Experimental
- AZD9833 with everolimus dose escalation · Experimental
- AZD9833 with abemaciclib (± anastrozole) dose escalation · Experimental
- AZD9833 with abemaciclib (± anastrozole)dose expansion · Experimental
- AZD9833 with capivasertib dose escalation · Experimental
- AZD9833 with capivasertib dose expansion · Experimental
- AZD9833 with ribociclib (± anastrozole) dose escalation · Experimental
- AZD9833 with ribociclib (± anastrozole) dose expansion · Experimental
- AZD9833 with anastrozole dose escalation · Experimental
- AZD9833 with anastrozole dose expansion · Experimental
- Enrollment
- 396
- Primary outcomes
- The number of subjects with dose-limiting toxicity, as defined in the protocol.
- The number of subjects with treatment-related adverse events as assessed by CTCAE v4.03.
- Sponsor
- AstraZeneca
- Start
- Oct 11, 2018
- Primary completion
- Sep 16, 2024
- Results posted
- No
- Registry record
- NCT03616587 · updated Aug 18, 2026